Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1
Prevalence and Risk Factors of HIV-associated Neurocognitive Impairment and Psychiatric Comorbidities in HIV-1 Infected Thai Individuals With Undetectable Viral Load in the HAART Era.
1 other identifier
observational
100
1 country
1
Brief Summary
To assess the prevalence and risk factors of neurocognitive impairment and psychiatric comorbidities in HIV infected patients who have undetectable viral load, have been on HAART for at least 1 year and have no history of CNS infection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2007
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2007
CompletedFirst Submitted
Initial submission to the registry
May 20, 2007
CompletedFirst Posted
Study publicly available on registry
May 22, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2008
CompletedJuly 17, 2020
July 1, 2020
1.1 years
May 20, 2007
July 15, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Neuropsychological testing score
1 day
Study Arms (1)
1
HIV infected adults with viral load \< 50 copies/ml on NNRTI based HAART
Interventions
lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
Eligibility Criteria
HIV infected adults with viral \< 50 copies/ml on NNRTI based HAART
You may qualify if:
- Signed informed consent
- Evidence of HIV infection (confirmed positive ELISA and documented history of measurable HIV RNA)
- Age \> 18 years old
- Plasma HIV RNA of \< 50 copies/ml within 3 months prior to screening
- Have been on only NNRTI-based HAART regimen for the entire duration and for at least1 year.
You may not qualify if:
- Current AIDS defining illnesses
- Current or history of previous CNS infection.
- Head injury with loss of consciousness greater than 1 hour
- Acute illness within 30 days prior to entry that, in the opinion of investigators, would prevent patients from completing the protocol required procedures.
- Known learning disability including dyslexia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The HIV Netherlands Australia Thailand Research Collaborationlead
- University of Hawaiicollaborator
- SEARCH Research Foundationcollaborator
- Chulalongkorn Universitycollaborator
- University of Missouri, Department of Psychology, Division of Neurosciencecollaborator
Study Sites (1)
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Bangkok, 10330, Thailand
Related Links
Biospecimen
PBMC and plasma
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jintanat Ananworanich, MD, Ph.D
The HIV Netherlands Australia Thailand Research Collaboration
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 20, 2007
First Posted
May 22, 2007
Study Start
March 1, 2007
Primary Completion
April 1, 2008
Study Completion
June 1, 2008
Last Updated
July 17, 2020
Record last verified: 2020-07